This is a narrative/credibility-building filing with no hard catalysts. Monitor for partner clinical trial readouts or new partnership announcements that could validate the platform thesis. No immediate trading action warranted.
Price Chart
Executive Summary
MindWalk released a report documenting over 20 drug candidates originating from its antibody discovery work, with 10 programs in active Phase 1-3 trials at partners. The filing is a promotional update on historical scientific output and AI platform integration, with no new financial data, guidance, or material business developments.
Key Facts
- Over 20 discovery-originated drug candidates documented; 10 in active Phase 1-3 clinical trials
- Partners include Annexon, argenx, Xencor, Cullinan Oncology, and others
- Knowledge Graph: 660 million biological patterns, 25 billion relationships
- Over 400 peer-reviewed publications and patents
- No financial data, guidance, or material agreements disclosed
Financial Impact
No financial figures reported; filing is a retrospective scientific and platform update
Risk Factors
- Partner programs may fail in clinical trials, undermining the discovery track record narrative
- No revenue or near-term monetization path disclosed; cash burn and dilution risk remain
- Forward-looking statements about AI platform value are unsubstantiated by financial results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-228179 |
| Document: press_release_may_18_202.htm | 0001193125-26-228179 |
| Document: 0001193125-26-228179-index-headers.html | 0001193125-26-228179 |
| Document: 0001193125-26-228179-index.html | 0001193125-26-228179 |
| Document: 0001193125-26-228179.txt | 0001193125-26-228179 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.16 | awaiting T+20 | — | $1.15 (−0.86%) |
Oct 21, 2026 6d ago | 6-K | $1.27 | awaiting T+20 | — | $1.15 (−9.45%) |
Oct 14, 2026 12d ago | 6-K | $1.37 | awaiting T+20 | — | $1.15 (−16.06%) |
Oct 6, 2026 20d ago | 6-K | $1.55 | awaiting T+20 | — | $1.15 (−25.81%) |
Sep 21, 2026 5w ago | 6-K | $1.47 $1.32 | ▼ −10.20% | ▼ −9.30% | $1.15 (−21.77%) |
Sep 14, 2026 6w ago | 6-K | $1.16 $1.48 | ▼ −28.14% | ▼ −25.16% | $1.15 (+0.43%) |
Sep 14, 2026 6w ago | 6-K | $1.33 $1.40 | ▲ +5.26% | ▲ +3.00% | $1.15 (−13.53%) |
Jul 31, 2026 12w ago | EFFECT | $1.29 $1.39 | ▲ +7.75% | ▲ +4.76% | $1.15 (−10.85%) |
Jul 6, 2026 16w ago | 6-K | $1.64 $1.29 | ▼ −21.34% | ▼ −20.78% | $1.15 (−29.88%) |
Jul 1, 2026 16w ago | 6-K | $1.62 $1.30 | ▼ −19.75% | ▼ −17.57% | $1.15 (−29.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers